A year after stunning China OK, Shanghai Alzheimer's drugmaker set to enroll first US patient — and the stakes are huge
Just as experts are set to debate whether Biogen’s aducanumab should become the first Alzheimer’s drug to be approved in the US in almost two …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
